La cadena de opciones muestra datos clave de las opciones de acciones de AbbVie a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para AbbVie..

AbbVie (NYSE:ABBV) Bolsa, Cadena de Opciones

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Eli Lilly and Co.

Equities

Government

News

Markets

ABBV

AMGN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

Interest,Rate,And,Dividend,Concept,,Personal,Investment,,,Return,On

Personal Finance

AVGO

HTGC

SCHD

Las 10 mejores participaciones en dividendos de un jubilado de Reddit, que vive cómodamente de los pagos de dividendos.

Jubilado comparte sus 10 principales participaciones en dividendos para una jubilación cómoda

CHWY

RIVN

ULTA

Descubre las acciones con mayor potencial en 2025 en belleza, salud y tecnología. ¿Qué estrategias impulsan su éxito?

Wall Street revela 4 acciones prometedoras: Sectores clave para invertir en 2025

AbbVie Inc

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
It will report its Q1 2025 earnings on April 25, before the market opens. Wall Street analysts expect the company to post EPS of $2.51, up from $2.31 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $12.91 billion, up from $12.31 billion a year earlier.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
The 52-week range of AbbVie stock price was $153.58 to $218.66.
AbbVie's dividend yield is 3.86%. It paid $6.56 per share in dividends during the last 12 months.
<h2 class="wp-block-heading">The Latest On AbbVie</h2>
On Jan. 31, the company announced its Q4 2024 earnings, posting adjusted EPS of $2.16, beating the street view of $2.11, as reported by <a href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline">Benzinga</a>. Quarterly sales came in at $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion.&nbsp;
AbbVie sees full-year 2025 adjusted EPS in the range of $12.12 to $12.32, compared to the street view of $12.18. The company reaffirmed its expectations for a high single-digit compound annual revenue growth rate through 2029.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44128338/13-analysts-have-this-to-say-about-abbvie">article by Benzinga</a> for 13 analysts' insights on AbbVie.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As An AbbVie Investor?</h2>
If you want to make $100 per month — $1,200 annually — from AbbVie dividends, your investment value needs to be approximately $31,088, which is around 183 shares at $170.16 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (3.86% in this case). So, $1,200 / 0.0386 = $31,088 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find AbbVie stock an attractive option for making a steady income of $100 per month by owning 183 shares of stock.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

How Much Would It Take To Earn $100 A Month From AbbVie Stock

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">U.S.-China trade relations.</a>
President Donald Trump claimed to have held a phone call with President Xi Jinping, yet Chinese officials denied that any talks had taken place.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) extended its rally into a fourth consecutive session, notching its best weekly performance of the year with a 16% gain. On Thursday afternoon, Transportation Secretary Sean Duffy introduced a new regulatory framework for self-driving vehicles, saying it aimed to reduce bureaucratic hurdles and advance toward a unified national standard.
T-Mobile US Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NYSE">TMUS</a>) was the biggest laggard of the day, falling 11%, on track for its worst single-day loss since March 2020. This came despite better-than-expected earnings, as its core wireless business posted slower growth than analysts had projected.
Among sectors, consumer discretionary led gains, buoyed by Tesla's 8% gain, while materials underperformed.
In fixed income, Treasury yields declined for a fourth straight session, underscoring how critical Trump's early-week reassurance — that he would not dismiss Fed Chair Jerome Powell — was for bond market sentiment.
The yield on the 10-year Treasury note dropped 4 basis points to 4.27%, on course for its lowest close since April 8.
In commodities, gold slid 2%, oil held steady at $62 per barrel, and natural gas rose 1% to $3 per million British thermal units, snapping a 10-session losing streak.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.2% to $95,000.
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,250.90</td>
<td>+0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,488.71</td>
<td>+0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,908.60</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,942.82</td>
<td colspan="2">-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $546.92.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.5% to $399.23.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $468.61.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $192.79.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.1%; the&nbsp;Materials Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings report included:
<ul>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): up 1.7%</li>
<li>T-Mobile US Inc.: down 10.9%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): up 2.4%</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>): down 7.2%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): down 3.2%</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>): down 11.0%</li>
<li>Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>): down 0.2%</li>
<li>Digital Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>): up 3.0%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>): down 5.2%</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>): up 10.3%</li>
<li>The Hartford Financial Services Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>): down 1.1%</li>
<li>Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>): down 2.1%</li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>): up 1.1%</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 7.7%</li>
<li>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): up 0.0%</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>): up 9.1%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>): down 2.0%</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 0.5%</li>
<li>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>): down 0.7%</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>): down 11.8%</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>): down 1.4%</li>
<li>Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>): down 6.0%</li>
<li>Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): down 4.7%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45009066/goldman-sachs-upgrades-charles-schwab-to-buy-one-of-the-best-earnings-growth-outlooks-analyst-says">Goldman Sachs Upgrades Charles Schwab To Buy: &#8216;One Of The Best Earnings Growth Outlooks,&#8217; Analyst Says</a></li>
</ul>
Photo: Shutterstock

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

CARR

CHTR

SPDR Dow Jones Industrial Average ETF Trust

ERIE

GOOGL

INTC

TMUS

TSLA

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?

AbbVie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock is trading higher after it released <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45005279/abbvie-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">better-than-expected Q1 earnings</a> and raised its 2025 forecast.
The company reported an adjusted EPS of $2.46 on Friday, up 6.5% year over year and beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.38</a>.
The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the consensus of $12.92 billion.
It reported adjusted earnings per share of $2.46, beating the street view of $2.38.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44937940/abbvies-pipeline-may-be-a-2026-story-but-analyst-likes-the-setup-now" rel="noreferrer noopener">AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now</a>
Global net revenues from the immunology portfolio were&nbsp;$6.26 billion, up 16.6% (+18.1% on an operational basis).
<ul>
<li>Skyrizi sales increased 70.5% (+72%) to $3.425 billion.</li>
<li>Rinvoq sales reached $1.72 billion, an increase of 57.2% (+59.7%).</li>
<li>Humira sales fell 50.6% (-49.5%) to $1.12 billion.</li>
</ul>
Oncology portfolio generated sales of&nbsp;$1.633 billion, up 5.8% (+7.5%).
<ul>
<li>Imbruvica's net revenues were $738 million, down 11.9%.</li>
<li>Venclexta's revenues were $665 million, up 8.3% (+12.3%).</li>
<li>Elahere revenues were $179 million.</li>
</ul>
Neuroscience portfolio sales were&nbsp;$2.282 billion, up 16.1% (+17%).
<ul>
<li>Vraylar net revenues were $765 million, up 10.3%.</li>
<li>Botox Therapeutic's net revenues were $866 million, up 15.8% (+17%).</li>
<li>Ubrelvy and Qulipta's net revenues were $240 million and $193 million, respectively.</li>
</ul>
Aesthetics sales were $1.102 billion, down 11.7% (-10.2%).
<ul>
<li>Botox Cosmetic sales decreased 12.3% (-10.7%) to $556 million.</li>
<li>Juvederm sales fell 22.2% (-20%) to $231 million.</li>
</ul>
"AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year," said&nbsp;Robert Michael, CEO of AbbVie. "The fundamentals of our business are strong, and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term."
Outlook:&nbsp;AbbVie&nbsp;raised the fiscal year 2025 adjusted EPS from $11.99-$12.19 to $12.09-$12.29 compared to the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $12.17</a>.
In January, AbbVie reaffirmed its forecast of high single-digit average annual revenue growth through 2029, using 2024 as the <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline" rel="noreferrer noopener">starting point for that calculation</a>.
<ul>
<li>The company also raised its long-term sales outlook for its immunology drugs, Skyrizi and Rinvoq. AbbVie expects the two drugs to bring in more than $31 billion in 2027—about $4 billion more than its previous estimate. That includes over $20 billion from Skyrizi and over $11 billion from Rinvoq.</li>
</ul>
Additionally, AbbVie updated its expectations for its aesthetics business, now projecting high single-digit average annual growth through 2029, starting from 2025.
William Blair writes, "Investors will be looking for greater clarity on the potential impacts of pharmaceutical tariffs on AbbVie's key brands, and the aesthetics business could face greater headwinds from macroeconomic uncertainty, but we continue to believe AbbVie has one of the cleanest revenue growth stories in the biopharma space over the next five years."
Analyst Matt Phipps maintains <a target="_blank" href="https://www.benzinga.com/quote/ABBV/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action:&nbsp;ABBV stock is trading higher by 1.13% at $182.41 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44994926/west-pharmaceutical-defies-doubters-eps-jumps-outlook-raised-despite-tariff-drag" target="_blank" rel="noreferrer noopener">West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Earnings

Guidance

Health Care

Analyst Ratings

Movers

Trading Ideas

General

AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector

WIIM

AbbVie shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) raises FY2025 Adj EPS guidance from $11.99-$12.19 to $12.09-$12.29 vs $12.17 analyst estimate..

AbbVie Raises FY2025 Adj EPS Guidance from $11.99-$12.19 to $12.09-$12.29 vs $12.17 Est

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $2.46 per share which beat the analyst consensus estimate of $2.38 by 3.36 percent. This is a 6.49 percent increase over earnings of $2.31 per share from the same period last year. The company reported quarterly sales of $13.34 billion which beat the analyst consensus estimate of $12.92 billion by 3.25 percent. This is a 8.39 percent increase over sales of $12.31 billion the same period last year.

Earnings Beats

AbbVie Q1 Adj. EPS $2.46 Beats $2.38 Estimate, Sales $13.34B Beat $12.92B Estimate

U.S. stock futures traded mixed on Friday after three consecutive days of gains, with S&amp;P 500 futures edging higher amid <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">rising earnings optimism</a> and signs of easing U.S.-China trade tensions.
The first quarter earnings report of Google-parent Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) topped estimates, adding to investor confidence following weeks of uncertainty.
Investors will be keeping an eye on AbbVie Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>),&nbsp;HCA Healthcare Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), and&nbsp;Aon PLC&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), among several other corporate earnings that are set to be released on Friday. 
U.S. 10-Year Treasury yields stood at 4.3% and 2-Year Treasury yields at 3.80%. According to the CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> predictions, there is a 95.3% chance of the Federal Reserve keeping interest rates unchanged during its next meeting in May.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.13%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.20%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.22%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.48%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) dipped 0.19% and 0.37%, respectively, in Friday's premarket trading, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;17jsfbw&#x2A;_gcl_au&#x2A;MjA5Njc0MjY1My4xNzQwODM2NTUw&#x2A;_ga&#x2A;R1MxLjEuMTc0NDY0ODA3Mi4yLjAuMTc0NDY0ODA3NS4wLjAuMA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NTU3MTI2OS4xLjEuMTc0NTU3MTQ4My4wLjAuMA..">Benzinga Pro</a> data.
Cues From Last Session: 
The markets were buoyed by the strong performance of Alphabet and T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), but several others, such as Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) and PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), fell short of estimates.
Economic data was largely mixed on Thursday, with the Initial Jobless Claims report at 220,000, against a forecast of 222,000, while Existing Home Sales came in at 4.03 million, falling short of the median forecast at 4.13 million.
All S&amp;P 500 sectors advanced on Thursday, barring consumer staples, which declined 0.88% owing to the lackluster earnings of PepsiCo and Procter &amp; Gamble during the day.
As of Thursday, the Nasdaq 100 was down 13.5% from its previous high of 22,222.61 points, the S&amp;P 500 was down 10.8% from a high of 6147.43 points, and finally, the Dow Jones Industrial Average was down 11% from its high of 45,073.63.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>2.74%</td>
<td>17,166.04</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>2.03%</td>
<td>5,484.77</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.23%</td>
<td>40,093.40</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2.00%</td>
<td>1,957.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts: 
Market analyst, Ryan Detrick, highlighted the fact that the S&amp;P 500 has risen by at least 1.5% for three trading days in a row, saying that, &#8220;This isn&#8217;t stuff you see in bear market rallies or short covering rallies.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 is up at least 1.5% for three days in a row. This isn&#39;t stuff you see in bear market rallies or short covering rallies. You see this before times of strong performance. Higher 10 out of 10 times a year later and up 21.6% on average. <a href="https://t.co/kfvfNKq6IK">pic.twitter.com/kfvfNKq6IK</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1915608371840921812?ref_src=twsrc%5Etfw">April 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;You see this before times of strong performance,&#8221; he says, &#8220;higher 10 out of 10 times a year later and up 21.6% on average,&#8221; each time you see three consecutive daily gains of 1.5% or more in the S&amp;P 500.
Upcoming Economic Data:
Here&#8217;s what investors will be looking at on Friday,
<ul>
<li>The Consumer Sentiment (Final) report is set to be released at 10 AM Eastern Time on Friday.</li>
</ul>
Stocks In Focus:
<ul>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is up 2.40% in pre-market trade as it is set to report its earnings this morning, with analysts expecting earnings of $2.40 per share, on $12.9 billion in revenue. </li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is down 0.43% pre-market and is set to report its earnings before the bell, with analysts expecting $5.75 per share, on $18.3 billion in revenue. </li>
<li>Aon PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) is set to report its earnings prior to the opening bell and is up 1.08% pre-market. Analysts expect earnings of $6.03 per share, on $4.8 billion in revenue. </li>
<li>Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is up 0.18% in pre-market trade in anticipation of its first quarter earnings prior to the opening bell. Analysts expect the FMCG giant to post $0.86 per share in earnings, on $4.8 billion in revenue. </li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) is down 4.8% in pre-market trade and is set to report its first quarter results before markets open. Analysts expect $8.59 per share in earnings and $13.7 billion in revenue.</li>
</ul>
Commodities, Gold And Global Equity Markets
Crude oil futures are trading down 0.68% in the early New York session on Friday, at $62.63 per barrel.
The U.S. Dollar Index (DXY) is up 0.37%, trading at 99.74, while gold spot prices continue to witness a pullback, trading at 3,299.63, down 1.08%.
Asian markets edged higher on Friday, with the Nikkei 225, Kospi, and Shenzhen ending the day in the green, along with Australia&#8217;s ASX 200. India&#8217;s Nifty 50 and the Sensex are ending the week down.
Image Via shutterstock

GOOG

US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says 'This Isn't Stuff You See In Bear Market'

<h3>Companies Reporting Before The Bell</h3>
• Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $572.09 million. 
• Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) is estimated to report quarterly earnings at $2.76 per share on revenue of $811.53 million. 
• Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) is estimated to report quarterly earnings at $1.00 per share on revenue of $814.11 million. 
• Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) is estimated to report quarterly earnings at $5.41 per share on revenue of $201.41 million. 
• Stellar Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEL#NYSE">STEL</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $105.66 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is estimated to report quarterly earnings at $4.38 per share on revenue of $6.64 billion. 
• Sensient Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXT#NYSE">SXT</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $387.70 million. 
• Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $623.41 million. 
• Flagstar Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) is expected to report quarterly loss at $0.28 per share on revenue of $509.58 million. 
• Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $970.49 million. 
• AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is likely to report quarterly earnings at $2.38 per share on revenue of $12.92 billion. 
• HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is expected to report quarterly earnings at $5.76 per share on revenue of $18.26 billion. 
• Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) is projected to report quarterly earnings at $8.69 per share on revenue of $13.68 billion. 
• Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is projected to report quarterly earnings at $0.74 per share on revenue of $8.60 billion. 
• Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) is expected to report quarterly loss at $0.72 per share on revenue of $31.33 billion. 
• Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $4.86 billion. 
• LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $7.46 billion. 
• Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) is expected to report quarterly earnings at $6.02 per share on revenue of $4.86 billion. 
• Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) is expected to report quarterly earnings at $2.54 per share on revenue of $43.36 billion. 
• Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) is expected to report earnings for its fourth quarter. 
• Lakeland Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKFN#NASDAQ">LKFN</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $63.71 million. 
• GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) is likely to report quarterly loss at $0.13 per share on revenue of $122.33 million. 
• Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $1.61 billion. 
• Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $9.90 million. 
• Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $654.15 million. 
• Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) is estimated to report quarterly earnings at $2.33 per share on revenue of $70.51 million. 
• Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) is likely to report quarterly earnings at $0.47 per share on revenue of $1.27 billion. 
• Trinet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) is projected to report quarterly earnings at $1.61 per share on revenue of $319.36 million. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

AVTR

GNTX

LKFN

OXSQ

PFBC

PHIN

RITM

SAIA

STEL

TNET

VRTS

Earnings Scheduled For April 25, 2025

U.S. stock futures are up Thursday night following <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">three back-to-back days</a> in the green during the regular session, amid growing earnings optimism and easing trade tensions.
The S&amp;P 500 Futures are up 0.37%, at 5,531, followed by Nasdaq Futures at 19,416, up 0.49%, and finally Dow Futures trading flat at 40,248, down 0.03%. All three major averages are up for the week, with one day left to go. 
See More: <a href="https://www.benzinga.com/25/04/44999320/japans-counterpunch-to-trump-tariffs-emergency-measures-deployed-as-us-trade-talks-loom">Japan&#8217;s Counterpunch To Trump Tariffs: Emergency Measures Deployed As US Trade Talks Loom</a>
Japan&#8217;s Nikkei 225 benchmark index opened higher on Friday morning, marking its third-straight session of gains. It is up 1.57%, or 528 points, at the time of writing this, taking cues from Wall Street. Tech stocks are leading the rally, while entertainment, retail, and real estate witness a pullback. Japan&#8217;s government has <a href="https://www.benzinga.com/25/04/44999320/japans-counterpunch-to-trump-tariffs-emergency-measures-deployed-as-us-trade-talks-loom">announced a number of emergency countermeasures</a> to combat the adverse effects of tariffs imposed by the United States.
The U.S. Dollar Index (DXY) is up 0.17%, trading at 99.55, and is now up 0.21% for the week, after hitting a three-year low of 97.96 on Monday. 
Investors will be waiting for the Consumer Sentiment Report on Friday morning, while also closely watching the earnings of AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), and Aon PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), among several others.
Photo Courtesy: Chokchai Poomichaiya on Shutterstock.com
Read More: <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">Wall Street Rally Extends Into Third Day: What&#8217;s Driving Markets Thursday?</a>

US Futures Gain Amid Back-To-Back Gains On Wall Street, Nikkei Opens In The Green, Dollar Edges Higher

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is gearing up to announce its quarterly earnings on Friday, 2025-04-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that AbbVie will report an earnings per share (EPS) of $2.51.
Anticipation surrounds AbbVie's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.10 in the last quarter, leading to a 0.0% drop in the share price on the following day.
Here's a look at AbbVie's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.26</td>
<td>2.92</td>
<td>2.57</td>
<td>2.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.16</td>
<td>3</td>
<td>2.65</td>
<td>2.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>1.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745503244_0_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of AbbVie were trading at $177.05 as of April 23. Over the last 52-week period, shares are up 10.83%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on AbbVie</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding AbbVie.
The consensus rating for AbbVie is Outperform, derived from 15 analyst ratings. An average one-year price target of $216.47 implies a potential 22.26% upside.
<h3>Comparing Ratings with Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Amgen, Gilead Sciences and Vertex Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Amgen, with an average 1-year price target of $309.43, suggesting a potential 74.77% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Gilead Sciences, with an average 1-year price target of $117.07, suggesting a potential 33.88% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Vertex Pharmaceuticals, with an average 1-year price target of $479.06, suggesting a potential 170.58% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Amgen, Gilead Sciences and Vertex Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>Outperform</td>
<td>5.60%</td>
<td>$10.71B</td>
<td>-0.68%</td>
</tr>
<tr>
<td>Amgen</td>
<td>Neutral</td>
<td>10.86%</td>
<td>$5.97B</td>
<td>9.36%</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>Outperform</td>
<td>6.40%</td>
<td>$5.99B</td>
<td>9.43%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>Neutral</td>
<td>15.66%</td>
<td>$2.49B</td>
<td>5.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
AbbVie ranks at the bottom for Revenue Growth and Gross Profit, while it ranks at the top for Return on Equity.
<h3>Get to Know AbbVie Better</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Financial Insights: AbbVie</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining AbbVie's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.6% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AbbVie's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.68%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): AbbVie's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.02%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 20.19, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/ABBV/earnings">To track all earnings releases for AbbVie visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of AbbVie's Earnings Potential

–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks.&nbsp; –If approved, TrenibotE&nbsp;will be the first neurotoxin of its kind available to patients. –Submission is supported by data from over 2,100 patients treated with TrenibotE throughout the clinical program.&nbsp;
NORTH CHICAGO, Ill., April 24, 2025 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)&nbsp;today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines.

Abbvie Submits Biologics License Application To FDA For trenibotulinumtoxinE For Treatment Of Moderate To Severe Glabellar Lines

Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of&nbsp;Cobenfy&nbsp;(xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia.
In the Phase 3 trial, adjunctive&nbsp;Cobenfy&nbsp;treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsychotic at Week 6, which did not reach the threshold for statistical significance for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44936890/bristol-myers-squibb-announces-topline-results-from-phase-3-arise-trial-evaluating-cobenfy-xanomel" rel="noreferrer noopener">primary endpoint (P = 0.11)</a>.
PANSS is used to assess the severity of positive and negative symptoms. It measures symptoms like hallucinations, delusions, and disorganized thinking, as well as negative symptoms like blunted affect and social withdrawal.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach</a>
Preliminary analyses suggest that&nbsp;Cobenfy&nbsp;as an adjunctive treatment to an atypical antipsychotic was associated with improvements in symptoms of schizophrenia compared to placebo plus an atypical antipsychotic for certain patients.
In a post-hoc subgroup analysis, there was a notable difference in response between subjects treated with risperidone as a background therapy compared with the remaining subjects treated with other background antipsychotics (non-risperidone).
Cobenfy's safety and tolerability profile as an adjunctive treatment was consistent with previous monotherapy trials.
Bristol Myers Squibb will complete a full evaluation of the Phase 3 trial data and intends to present detailed results at an upcoming medical conference.
In September 2024, the FDA approved&nbsp;Cobenfy, an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41073709/absence-of-black-box-warning-for-bristol-myers-schizophrenia-treatment-could-enhanc" rel="noreferrer noopener">schizophrenia in adults</a>.
Data from the EMERGENT clinical program supported the FDA approval of Cobenfy. In Phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary endpoint, demonstrating statistically significant reductions of schizophrenia symptoms compared to placebo from baseline to week five.
William Blair viewed "the ARISE trial as one that could accelerate the uptake of Cobenfy overall, increasing physician confidence in the adjunctive setting ahead of their own personalized approaches."
Even though this setback might lower the chances of strong short-term results, Analyst Matt Phipps still sees a big long-term potential for Cobenfy, with estimated global sales reaching $3.7 billion for schizophrenia.
Bristol is expected to report first-quarter earnings on Thursday, April 24 and it is expected management to provide additional details on the study's impact to the launch curve for Cobenfy and longer-term opportunity.
"The opportunity in Alzheimer's disease psychosis is the next key readout for Cobenfy, where we see significant market opportunity assuming clinical success and a tolerable safety profile," analyst Phipps writes.
In November 2024, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the PANSS total score compared to the placebo group at week 6.
Last year, Leerink analyst estimated the potential for peak Cobenfy sales of over $10 billion if it succeeds in additional indications since&nbsp;Eli Lilly And Co's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zyprexa generated $5 billion in peak revenue in 2010 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock" rel="noreferrer noopener">at much lower prices</a>.
Price Action: BMY stock is down 2.95% at $48.35 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44938762/draftkings-may-trim-2025-forecast-amid-texas-jackpocket-shutdown-says-analyst" target="_blank" rel="noreferrer noopener">DraftKings May Trim 2025 Forecast Amid Texas Jackpocket Shutdown: Analyst</a></li>
</ul>
Photo via Shutterstock

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/22/final-trades-3m-abbvie-salesforce-and-intuitive-surgical.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown, CEO and co-founder, Ritholtz Wealth Management, said he is staying long on 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>).
Supporting his view, 3M reported better-than-expected first-quarter financial results on Tuesday. The company reported net sales of $5.95 billion, a 1.0% decline year-over-year (Y/Y), beating the consensus of $ 5.78 billion. Adjusted EPS was $1.88, up 10% Y/Y, beating the <a href="https://in.benzinga.com/news/earnings/25/04/44921668/3m-stock-surges-after-q1-beat-as-2025-outlook-flags-tariff-pressure">consensus of $1.77</a>.
Jim Lebenthal of Cerity Partners picked AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) as his final trade.
Lending support to his choice, Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie on Tuesday with an Overweight rating and a price target of $210.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Rob Sechan of New Edge Capital Group named Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) as his final trade.
Guggenheim analyst John Difucci upgraded Salesforce from Sell to Neutral on Monday.
Stephanie Link of Hightower picked Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) as her final trade.
On the earnings front, Intuitive Surgical reported first-quarter revenue of $2.25 billion on Tuesday, beating analyst estimates of $2.19 billion. The robotic-assisted surgery company reported first-quarter adjusted earnings of $1.81 per share, beating analyst estimates of $1.72 per share.
Price Action:
<ul>
<li>3M shares jumped 8.1% to close at $136.33 on Tuesday.</li>
<li>AbbVie gained 2.1% to close at $173.78 during Tuesday's session.</li>
<li>Salesforce shares rose 3% to close at $243.39 on Tuesday.</li>
<li>Intuitive Surgical shares climbed 2.2% to settle at $478.74 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44920101/top-2-tech-and-telecom-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech And Telecom Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

ISRG

Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades'

Analysts' ratings for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AbbVie, revealing an average target of $216.47, a high estimate of $241.00, and a low estimate of $190.00. This current average has increased by 3.01% from the previous average price target of $210.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1745355625_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of AbbVie by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Carter Gould &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Overweight &#x7C; $210.00&#x7C;- &#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $214.00&#x7C;$214.00 &#x7C; 
&#x7C;Terence Flynn &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $241.00&#x7C;$239.00 &#x7C; 
&#x7C;Asad Haider &#x7C;Goldman Sachs &#x7C;Announces &#x7C;Neutral &#x7C; $194.00&#x7C;- &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $240.00&#x7C;$210.00 &#x7C; 
&#x7C;Tim Anderson &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $223.00&#x7C;$200.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $215.00&#x7C;$205.00 &#x7C; 
&#x7C;Srikripa Devarakonda&#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $217.00&#x7C;$211.00 &#x7C; 
&#x7C;Navin Jacob &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $190.00&#x7C;$181.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $210.00&#x7C;$195.00 &#x7C; 
&#x7C;Terence Flynn &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $239.00&#x7C;$224.00 &#x7C; 
&#x7C;Gary Nachman &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $220.00&#x7C;$218.00 &#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $214.00&#x7C;$212.00 &#x7C; 
&#x7C;Evan David Seigerman&#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $215.00&#x7C;$208.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $205.00&#x7C;$215.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into AbbVie's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AbbVie analyst ratings.</a>
<h2>Delving into AbbVie's Background</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>A Deep Dive into AbbVie's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining AbbVie's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.6% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AbbVie's ROE excels beyond industry benchmarks, reaching -0.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.02%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: AbbVie's debt-to-equity ratio stands notably higher than the industry average, reaching 20.19. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For AbbVie's Future

Cantor Fitzgerald initiated coverage on AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), citing the company&#8217;s compelling mix of growth and defense with a differentiated topline profile, good visibility on key near-term drivers with low clinical risk, no significant near-to-mid-term patent loss, and a lack of a major <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">binary data catalyst over 2025</a>.
&#8220;We acknowledge the pipeline still has a lot to prove, but think it also has limited value ascribed to it, and we see that as more of the &#8217;26 narrative,&#8221; analyst Carter Gould writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
With AbbVie stock trading around $180 per share—about 14.1 times its expected 2025 earnings, or 16.3 times when including Skyrizi royalties—analyst Gould sees the stock as appealing as it&#8217;s been over the past six months, despite the possibility of higher tariff costs in 2026.
Cantor sees AbbVie&#8217;s immunology drugs, Skyrizi and Rinvoq, as strong and unique in the market. They already have a solid presence and are growing quickly without relying heavily on new clinical trial results. Plus, there&#8217;s no major concern about losing patent protection until after 2033. Recent prescription trends support this view, showing strong overall growth for both drugs. In particular, their use in gastroenterology is a key driver, growing over 40% year-over-year.
Cantor initiated with an Overweight rating and <a target="_blank" href="https://www.benzinga.com/quote/ABBV/analyst-ratings" rel="noreferrer noopener">a price target of 210</a>.
AbbVie is scheduled to release its first quarter <a href="https://www.benzinga.com/pressreleases/25/03/n44559336/abbvie-to-host-first-quarter-2025-earnings-conference-call" target="_blank" rel="noreferrer noopener">earnings on Friday</a>. Analysts estimate $2.51 per share earnings and sales of around $12.91 billion as per data from <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
In March, AbbVie and&nbsp;Gubra A/S&nbsp;announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44089215/abbvie-becomes-another-big-pharma-to-enter-obesity-treatment-race" rel="noreferrer noopener">Phase 1 clinical trial</a>.
Under the terms of the agreement, AbbVie will lead the development and commercialization activities of GUB014295 globally.
Gubra will receive&nbsp;$350 million&nbsp;in total upfront payment and be eligible to receive up to&nbsp;$1.875 billion&nbsp;in development, commercial and sales milestone payments with tiered royalties on global net sales.
Price Action: ABBV stock was up 2.1% at $173.78 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44928729/rigetti-scores-4-6-million-uk-grant-to-tackle-quantum-error-correction" target="_blank" rel="noreferrer noopener">Rigetti Scores $4.6 Million UK Grant To Tackle Quantum Error Correction</a></li>
</ul>
Photo: Shutterstock

Initiation

AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 24 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 29%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $453,669, and 17 are calls, for a total amount of $1,349,576.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $130.0 to $205.0 for AbbVie over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of AbbVie stands at 1079.89, with a total volume reaching 3,785.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $130.0 to $205.0, throughout the last 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745352119_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.45</td>
<td>$7.25</td>
<td>$7.45</td>
<td>$172.50</td>
<td>$223.5K</td>
<td align="right">600</td>
<td align="right">302</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$7.9</td>
<td>$7.7</td>
<td>$7.78</td>
<td>$190.00</td>
<td>$165.7K</td>
<td align="right">330</td>
<td align="right">271</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$5.2</td>
<td>$5.15</td>
<td>$5.2</td>
<td>$180.00</td>
<td>$157.5K</td>
<td align="right">38</td>
<td align="right">384</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$8.8</td>
<td>$8.45</td>
<td>$8.65</td>
<td>$165.00</td>
<td>$136.6K</td>
<td align="right">349</td>
<td align="right">216</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.7</td>
<td>$10.55</td>
<td>$10.7</td>
<td>$180.00</td>
<td>$133.7K</td>
<td align="right">467</td>
<td align="right">125</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a volume of 3,896,116, the price of ABBV is up 2.39% at $174.22. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 3 days.</li>
</ul>
<h3>What Analysts Are Saying About AbbVie</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $214.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs downgraded its action to Neutral with a price target of $194. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $210. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on AbbVie, maintaining a target price of $241. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $214. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on AbbVie: Analyzing the Surge in Options Activity

CNBC Halftime Report Final Trades: 3M Company, AbbVie, Salesforce, Intuitive Surgical

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Nicholas Campanella upgraded the rating for CenterPoint Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) from Underweight to Equal-Weight and raised the price target from $30 to $37. CenterPoint Energy shares closed at $36.49 on Monday. <a href="https://www.benzinga.com/quote/CNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Gustavo Schroden upgraded PagSeguro Digital Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGS#NYSE">PAGS</a>) from Neutral to Buy and raised the price target from $7 to $10. PagSeguro Digital shares closed at $8.47 on Monday. <a href="https://www.benzinga.com/quote/PAGS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Gustavo Schroden upgraded the rating for StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) from Neutral to Buy and boosted the price target from $9 to $15. StoneCo shares closed at $12.06 on Monday. <a href="https://www.benzinga.com/quote/STNE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David Koning upgraded Verra Mobility Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRRM#NASDAQ">VRRM</a>) from Neutral to Outperform and maintained the price target of&nbsp;$27. Verra Mobility shares closed at $20.99 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Stephen Grambling upgraded the Marriott Vacations Worldwide Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) from Underweight to Equal-Weight but lowered the price target from $67 to $57. Marriott Vacations shares closed at $52.80 on Monday.  <a href="https://www.benzinga.com/quote/vac/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying STNE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22074047/image-44-1024x586.png" alt="" class="wp-image-881647" style="width:517px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22074047/image-44-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22074047/image-44-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22074047/image-44-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22074047/image-44.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Upgrades

PAGS

STNE

VRRM

This StoneCo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Mike Cikos initiated coverage on CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Buy rating and announced a price target of $55. CoreWeave shares closed at $35.42 on Monday. <a href="https://www.benzinga.com/quote/CRWV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst John Dunigan initiated coverage on Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Hold rating and announced a price target of $175. Avery Dennison shares closed at $169.03 on Monday. <a href="https://www.benzinga.com/quote/AVY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Kevin Cassidy initiated coverage on Blaize Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Neutral rating and announced a price target of $3. Blaize Holdings shares closed at $2.67 on Monday. <a href="https://www.benzinga.com/quote/BZAI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Eric Beaumont initiated coverage on American Water Works Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) with an Underweight rating and announced a price target of $138. American Water Works shares closed at $147.13 on Monday. <a href="https://www.benzinga.com/quote/AWK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Carter Gould initiated coverage on AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with an Overweight rating and announced a price target of $210. AbbVie shares closed at $170.16 on Monday.  <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AWK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="625" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-1024x625.png" alt="" class="wp-image-881626" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-1024x625.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

BZAI

CRWV

This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday

Cantor Fitzgerald analyst Carter Gould initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight rating and announces Price Target of $210.

Price Target

Cantor Fitzgerald Initiates Coverage On AbbVie with Overweight Rating, Announces Price Target of $210

Press Releases

The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors – Contact Levi & Korsinsky

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders

Legal

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV

The Gross Law Firm Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV

AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

Lost Money on Cerevel Therapeutics Holdings, Inc.(ABBV)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV

AbbVie Reports First-Quarter 2025 Financial Results

Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

AbbVie

AbbVie (ABBV) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL